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Abstract
Objectives: Hypertension is the leading modifiable cause of mortality worldwide. Unlike many conditions where
limited evidence exists for management of older individuals, multiple large, robust trials have provided a solid
evidence-base regarding the management of hypertension in older adults. Understanding the impact of age on
how the prevalence of hypertension and the role of pharmacotherapy in managing hypertension among older
persons is a critical element is the provision of optimal health care for older populations. The aim of this study was to
explore how the prevalence of hypertension changes with age, the evidence regarding pharmacological management
in older adults and to identify known barriers to the optimal management of hypertension in older patients.
Methods: A review of English language studies published prior to 2013 in Medline, Embase and Google scholar was
conducted. Key search terms included hypertension, pharmacotherapy, and aged.
Results: The prevalence of hypertension was shown to increase with age, however there is good evidence for the use
of a number of pharmacological agents to control blood pressure in older populations. System, physician and patient
related barriers to optimal blood pressure control were identified.
Conclusions: Despite good evidence for pharmacological management of hypertension among olderpopulations,
under treatment of hypertension is an issue. Concerns regarding adverse effects appearcentral to under treatment of
hypertension among older populations.
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Introduction
Population aging has considerable implications for health
care systems internationally, especially from the perspec-
tive of pharmaceutical practice and policy. “Older adults”
are commonly defined in the medical literature as individ-
uals aged 65 years or over [1]. Internationally, the propor-
tion of the population defined as older adults is increasing,
primarily as a result of the increase in life expectancy [2].
By 2050 it is anticipated that older population will account
for 21 % of the total population in most developed coun-
tries [3], while in some countries, such as Japan, older
adults already represent one-fifth of the total population
[4, 5]. A similar increase applies to the very old adults
(age ≥80 years), one of the fastest growing segments
of older adults population and one that is expected to
triple by 2050 [6].
Hypertension is the leading modifiable cause of mortal-
ity worldwide [7]. Unlike many conditions where limited
evidence exists for management of those aged over
65 years due to the exclusion of older populations from
clinical trials [8, 9], the findings of multiple large, robust
trials have provided a solid evidence-base regarding the
management of hypertension in older adults [7]. Adverse
outcomes associated with poor blood pressure (BP) con-
trol in older persons have been well documented. A
Cochrane review of 12 clinical trials showed that the man-
agement of hypertension in people aged 60 years and over
was associated with a reduction in mortality (Relative Risk
(RR)) = 0.9, 95 % confidence interval ((CI) 0.84–0.97) [10].
The same review reported pharmacological management
of hypertension in older adults was associated with
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significant reductions in both cardiovascular (RR = 0.77,
95 % CI 0.68–0.86) and cerebrovascular mortality (RR =
0.66, 95 % CI 0.53–0.82) [10].
Given the expected increase in the older adult popula-
tion and the wealth of evidence regarding the manage-
ment of hypertension in older persons, understanding
how the prevalence of hypertension changes with age as
well as how physicians currently manage older patients
with increased BP is important. Furthermore, insight into
current barriers to the provision of optimal management is
essential if clinicians are to meet the health needs of the
growing older populations. The aim of this study was to
provide an overview of the prevalence of hypertension and
its pharmacological management in older adults. A sec-
ondary aim was to explore known barriers to the optimal
management of hypertension in older patients.
Methods
Narrative review methodology as described by Green et al.
[11] was used to conduct a non-systematic narrative review
of the literature regarding pharmacotherapy for the man-
agement of hypertension in older populations.
Data sources and study selection
An electronic search of the electronic databases EMBASE,
MEDLINE for studies published prior to 2013 regarding
the use of pharmacotherapy for the pharmacological man-
agement of hypertension among older populations was
conducted. In addition, Google scholar was searched to
identify any non-indexed relevant publications. Search
terms used included: hypertension, pharmacotherapy, and
aged. Additional search terms used included: drug therapy,
elderly, older patients, and geriatric. Search terms were
mapped to MESH headings in Medline and EMTREE
headings in Embase. Studies which focused specifically on
pharmacological management of hypertension in older
persons were included in the review. Exclusion criteria
were non-English language studies, studies in non-human
populations as well as studies that did not specifically
focus on populations aged 65 years and older or on
pharmacological management of hypertension.
Data synthesis
A narrative synthesis of the prevalence of hypertension in
older populations, the evidence regarding the use of differ-
ent pharmacological agents and identification of barrier to
optimal pharmacological management of hypertension
among older persons was conducted.
Review
Prevalence of hypertension in older populations
Data from the Framingham study in 1978 and 2002
[12–14] and the 2005 US National Health and
Nutrition Survey (NHANES) [15] have shown clear in-
creases in the prevalence of hypertension with age
(Fig. 1). The original Framingham study followed 5209
respondents from 1948 until 2005, exploring the devel-
opment of cardiovascular disease and identification of
associated risk factors over time [2, 3]. The NHANES
surveys are annual cross sectional surveys which com-
bine interview and physical examination, to assess
health status across representative samples of the
American population.[15] The NHANES data demon-
strated that increases in the prevalence of hypertension
prevalence begin in adulthood, with the prevalence doub-
ling between the ages of 20–40 years, and then with a fur-
ther 100 % increase occurring between 40 and 60 years.
The Framingham study showed that this pattern con-
tinues as people age, with the prevalence of hypertension
increasing from 27.3 % in those aged ≥ 60 years to 74.0 %
in those aged over 80 years.
Gender differences in the prevalence of hypertension
have been noted in both younger and older populations. A
number of studies have shown found that although
women have a lower prevalence of hypertension than men
at a younger ages, this pattern changes after the age of
60 years when the pattern reverses with the prevalence in
women exceeding that in men.[13, 16–21],
Differences have been reported in terms of aging with re-
spect to increases in systolic blood pressure (SBP) com-
pared with diastolic blood pressure (DBP). Both systolic
and diastolic pressure have been reported to increase with
age. [15] This increase continues until the ninth decade
however it is believed that DBP may plateau or even
decrease around the age of 60 years. [15] These differences
may account for the increase in isolated systolic hyperten-
sion that is associated with aging. Isolated systolic hyper-
tension refers to elevated SBP with a normal DBP. [22] .
Pathophysiological changes including increased per-
ipheral vascular resistance due to arterial stiffening,
which occur with age, are believed to be one factor as-
sociated with the increase in hypertension associated
with aging. [15, 23]. This increase in arterial stiffness with
ageing is believed to alter the normal hemodynamic pat-
tern of blood pressure (BP) causing an increased pulse
wave velocity, an index of arterial stiffness, and widening
pulse pressure therefore accounting for the observed age–
related decline in DBP and increase in SBP. [17, 23–25].
Other factors such as the changes in renin and aldoster-
one levels, decreases in renal salt excretion, age-related
declines in renal function and associated changes in the
autonomic nervous system and endothelial function are
also considered contributory factors.[16, 26–28]. Life style
related factors might also contribute to the development
of hypertension. Factors such as stress, excessive alco-
hol intake, sedentary life style, high sodium intake and
obesity are risk factors for hypertension [16, 29–31].
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Moreover a synergistic effect on the risk of hyperten-
sion has been observed when multiple factors exist syn-
chronously [16, 29–31].
Pharmacological management of hypertension in the
elderly
While life-style interventions are generally the first-line
strategy for the management of all persons with hyperten-
sion, the majority of hypertensive patients will require
pharmacological intervention to adequately control their
blood pressure. [32]. A number of large well-conducted
clinical trials exploring pharmacological management of
hypertension in the elderly have been conducted and there
is good evidence for the use of a variety of different anti-
hypertensive agents in the management of hypertension
in the elderly. [10]
Thiazide and thiazide –like diuretics
Thiazides diuretics are one of the oldest drug classes
used in the treatment of hypertension. [33] Evidence of
effectiveness in lowering BP and preventing the cardio
and cerebrovascular adverse outcomes associated with
hypertension in the elderly has been supported by sev-
eral clinical trials, including the Hypertension in the
very elderly (HyVET) [34], the Swedish Trial in Old
Patients with Hypertension (STOP)[35, 36] and the
Antihypertensive and Lipid-Lowering Treatment to
prevent Heart Attack Trial (ALLHAT) [37] studies
While not all these studies focused specifically on the
elderly, the mean participant age was over 65 years for
all, and their recommendations were especially relevant
for the younger elderly population.
Use of thiazide and thiazide like diuretics for the man-
agement of hypertension in older persons has declined
over the past decade. [19, 20, 38–40]. There are a number
of possible explanations for this change in the pattern of
thiazide prescribing including increased use of other
diuretics, particularly in elderly with complicated hyper-
tension [41, 42], the advent of other antihypertensive
medications such as Calcium Channel Blockers (CCBs)
or agents acting on the Renin Angiotensin System
(RAS), as well as greater caution by prescribers due to
increased risk of adverse drug reactions in elderly [43, 44].
Yet, despite this general decline in thiazide use among
older persons with hypertension, their use remains high
[15, 45, 46], and they are the most commonly used agents
in combination therapy in the management of hyperten-
sion. [19, 20, 38, 39, 45, 47].
Agents acting on the Renin-Angiotensin System (RAS)
There are three main three antihypertensive classes that
act on RAS. These are the angiotensin receptor
blockers (ARBs), the Angiotensin concerting enzyme
inhibitors (ACEI) and the direct renin inhibitors. The
use of both ARBs [15, 38, 45] and ACEIs [15, 19, 20,
38, 40, 45, 47–49] in the elderly is generally high, and
has increased over years surpassing other antihyperten-
sive classes such as CCBs. The increase in use of these
agents has been supported by clinical trials such as the
Second Australian National Blood Pressure (ANBP2)
[50] which demonstrated that ACEI were superior to
thiazide diuretics in terms of cardiovascular outcomes,



























Fig. 1 Increasing prevalence of hypertension with age
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in terms of all cause mortality. In addition to increased
use as monotherapy, ACEI and ARB use in combin-
ation with other antihypertensive medications has also
increased over recent years [19, 20, 38, 39, 45, 47]. In
contrast to the common use of ACEIs and ARBs, use of
aliskiren, a direct renin inhibitor that has been ap-
proved for use since 2007 in elderly hypertension pa-
tients is minimal[15, 47]. The slow uptake of aliskiren
for use among the elderly may be hindered by its lim-
ited efficacy and relatively poor safety profile.[51, 52]
Calcium channel blockers (CCBs)
Since the introduction of CCBs, the prescribing pattern of
this antihypertensive medication class in the elderly has
increased both as monotherapy and combination therapy.
[15, 20, 39, 48, 49] Despite publication of the Systolic
Hypertension in the Europe Trial (SYST-EUR) in 1997
which showed that treating 1000 patients for 5 years with a
CCB regimen prevents 29 strokes or 53 MIs [53], a decline
in the use of CCBs has generally been noticed in elderly
and very elderly patients since the mid 1990s has been
observed. [19, 38, 45] This decline in use may be secondary
to proposed safety concerns including increased risk of can-
cer, myocardial infarction and gastrointestinal heamorrhage
with long term use [54–56].
Beta blockers (BBs)
Beta blockers were among the most commonly prescribed
agents since their introduction as an option for the treat-
ment of hypertension [40, 47, 48]. However, use in the
elderly has decreased [19, 20, 38, 39, 43]. following
publication of a meta-analyses raising questions about their
efficacy and highlighting safety concerns with an increased
risk of stroke reported with BB use as monotherapy [57].
The current low rate of use was highlighted in a recently
published observational study. [45]
Alpha blockers
While several studies have shown a slight increase in the
use of alpha blockers in the management of hypertension
in the elderly and very elderly patients [15, 40], overall
their use has declined [20, 45, 47, 48]. This decline in use
may be due to the poor adverse effect profile of the alpha
blockers in the elderly as well as to a lack of evidence in
preventing cardiovascular related complications when
compared with other antihypertensive agents.
Barriers to the optimal management of hypertension in
the elderly
Despite the wealth of evidence regarding the benefits of
managing hypertension in older and very old popula-
tions, a substantial proportion of older persons have
suboptimal blood pressure control. [58]. A number of
barriers to optimal blood pressure control in the elderly
have been identified and these barriers can generally be
considered as system-, physician- or patient-related
barriers.
System–related barriers affecting blood pressure control
in the elderly include the variability in treatment recom-
mendations for this population. [59, 60]. While a number
of clinical trials have been conducted in the elderly, the
extent to which this evidence has been incorporated into
treatment guidelines and translated into practice remains
unknown.
Physician-related barriers include differences in phys-
ician attitudes towards the risks and benefits of managing
hypertension in older persons as well as differences in
interpretation of the evidence. [61–64]. Inconsistency be-
tween treatment guidelines regarding management of
hypertension in the elderly may make it difficult for clini-
cians to incorporate the evidence-based recommendations
in their daily clinical practice. [61, 62, 65]. The lack of
consistency in guidelines may also influence prescribing
decisions in the treatment of complex patients, such as
those with multiple co-morbidities. [61, 63, 66, 67]
Patient awareness of their condition may also influence
medication use and BP control. Patients with a higher
awareness of the need for regular blood pressure monitor-
ing are more likely to have controlled blood pressure, [63,
66–70] while those with poorer adherence to prescribed
medication are less likely to have controlled BP. [18, 71–74]
Adverse drug reactions may influence both the clini-
cian’s decision to prescribe a medication[75, 76], as well as
the patient’s decision to continue using a medication [66],
and more work is needed to better understand the role
adverse drug reactions play in the use of antihypertensive
medications in the elderly.
Unlike a systeamtic review where the aim is to capture
all revelant literature, as a non-systematic narrative review,
the aim of this study was to provide an wide overview of
the prevalence of hypertension and its pharmacological
management in older adults. To cover a wide range of
published literature, searches were conducted in both
Medline and Embase electronic databases. In addition, a
general search of Google scholar was also conducted to
capture relevant published work not indexed in either
Medline or Embase. However inclusion of other databases
may have widened the range of literature included in the
analysis and is one limitation of this work.
Conclusion
The prevalence of hypertension increases significantly
with age. While approximately 30 % of the adult popula-
tion aged less than 65 years has hypertension, by the age
of 80 over 70 % of the population has or is being treated
for elevated blood pressure. The estimated direct and
indirect economic impacts and medical expenditure of
hypertension is high and, given predicted increases in the
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elderly population, likely to increase. Despite the availabil-
ity of effective antihypertensive medications and good
evidence for blood pressure reduction in older popula-
tions, current management, management appears subopti-
mal. Barriers to optimal blood pressure control in older
populations are often multifactorial highlighting the clin-
ical complexity of this patient population. System, pre-
scriber and patient related barriers to the management of
hypertension exist and is interplay between these such as
the lack of clinical guidance regarding management of
hypertension in complex older patients with multiple
comorbidities contribute to suboptimal blood pressure
control in older populations.
Abbreviations
RR: Relative risk; CI: Confidence interval; SBP: Systolic blood Pressure;
DBP: Diastolic blood pressure; BP: Blood pressure; RAS: Renin angiotensin
system; ARB: Angiotensin receptor blocker; ACEI: Angiotensin concerting
enzyme inhibitor; CCB: Calcium channel blocker; BB: Beta blocker.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
MK, IS, BS and LR proposed and designed the experiments. MK and BW
performed the experiments, MK and LR analyzed the bioinformatics data and
LR prepared phylogenetic trees. MK, IS, BS, and LR wrote the paper. All
authors approved the final manuscript.
Author details
1Faculty of Pharmacy, University of Sydney, Sydney, Australia. 2College of
Pharmacy, King Saud University, Riyadh, Saudi Arabia. 3Centre for Health
Systems and Safety Research, Australian Insititue of Health Innovation,
Macquarie University, North Ryde, Australia.
Received: 11 December 2014 Accepted: 1 September 2015
References
1. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/
AHA 2011 Expert Consensus Document on Hypertension in the ElderlyA
Report of the American College of Cardiology Foundation Task Force on
Clinical Expert Consensus Documents Developed in Collaboration With the
American Academy of Neurology, American Geriatrics Society, American
Society for Preventive Cardiology, American Society of Hypertension,
American Society of Nephrology, Association of Black Cardiologists, and
European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114.
2. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science.
2002;296:1029–31.
3. United Nations Department of Economic and Social Affairs Population
Division. World Population Aging: 1950-2050. New York: United Nations;
2001.
4. He W, Sengupta M, Velkoff VA, DeBarros KA. U.S. Census Bureau, Current
Population Reports, P23-209, 65+ in the United States: 2005. Washington
DC: U.S. Government Printing Office; 2005.
5. Ogawa N, Matsukura R. Ageing in Japan: the health and wealth of older
persons. In United Nations expert group meeting on social and economic
implications of changing population age structures. 2007;199–220.
6. United Nations, Department of Economic and Social Affairs, Population
Division. World Population Ageing 2013. New York: United Nations, 2013.
7. Pimenta E, Oparil S. Management of hypertension in the elderly. Nat Rev
Cardiol. 2012;9:286–96.
8. White SM. Including the very elderly in clinical trials. Anaesthesia.
2010;65:778–80.
9. Devlin G. Women and elderly: subgroups under-represented in clinical trials.
Curr Opin Cardiol. 2010;25:335–9.
10. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for
hypertension in the elderly. Cochrane Database Syst Rev. 2009;7(4).
CD000028.
11. Green BN, Johnson CD, Adams A. Writing narrative literature reviews for
peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101–17.
12. Kannel WB, Gordan T. Evaluation of cardiovascular risk in the elderly. The
Framingham study. Bull N Y Acad Med. 1978;54(6):573–91.
13. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al.
Hemodynamic patterns of age-related changes in blood pressure The
Framingham Heart Study. Circulation. 1997;96:308–15.
14. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al.
Residual lifetime risk for developing hypertension in middle-aged women
and men: The Framingham Heart Study. JAMA. 2002;287(8):1003–10.
15. Bromfield SG, Bowling CB, Tanner RM, Peralta CA, Odden MC, Oparil S, et al.
Trends in hypertension prevalence, awareness, treatment, and control
among US adults 80 years and Older, 1988–2010. J Clin Hypertens.
2014;16(4):270–76.
16. Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S.
Hazzard's Geriatric Medicine and Gerontology, 6th Edition. USA: McGraw-
Hill; 2009.
17. Mann SJ. Systolic hypertension in the elderly: pathophysiology and
management. Arch Intern Med. 1992;152:1977–84.
18. Lu F-H, Tang S-J, Wu J-S, Yang Y-C, Chang C-J. Hypertension in elderly
persons its prevalence and associated cardiovascular risk factors in Tainan
city, southern Taiwan. J Gerontol A Biol Sci Med Sci. 2000;55:M463–8.
19. Primatesta P, Poulter NR. Hypertension management and control among
English adults aged 65 years and older in 2000 and 2001. J Hypertens.
2004;22:1093–8.
20. Trenkwalder P, Ruland D, Stender M, Gebhard J, Trenkwalder C, Lydtin H, et
al. Prevalence, awareness, treatment and control of hypertension in a
population over the age of 65 years: results from the Starnberg Study on
Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY). J
Hypertens. 1994;12:709.
21. Gambassi G, Lapane K, Sgadari A, Landi F, Carbonin P, Hume A, et al.
Prevalence, clinical correlates, and treatment of hypertension in elderly
nursing home residents. Arch Intern Med. 1998;158:2377–85.
22. Franklin SS, Jacobs MJ, Wong ND, Gilbert J, Lapuerta P. Predominance of
isolated systolic hypertension among middle-aged and elderly US
hypertensives analysis based on National Health and Nutrition Examination
Survey (NHANES) III. Hypertension. 2001;37:869–74.
23. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al.
Changes in arterial stiffness and wave reflection with advancing age in
healthy men and women the Framingham Heart Study. Hypertension.
2004;43:1239–45.
24. Pinto E. Blood pressure and ageing. Postgrad Med J. 2007;83:109–14.
25. Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, Sakkinen PA, Lyles MF,
Spurgeon HA, et al. Correlates of aortic stiffness in elderly individuals: a
subgroup of the Cardiovascular Health Study. Am J Hypertens.
2002;15:16–23.
26. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension.
1996;27:481–90.
27. Fliser D, Ritz E. Relationship between hypertension and renal function and
its therapeutic implications in the elderly. Gerontology. 1998;44:123–31.
28. Wallace SM, McEniery CM, Mäki-Petäjä KM, Booth AD, Cockcroft JR,
Wilkinson IB. Isolated systolic hypertension is characterized by increased
aortic stiffness and endothelial dysfunction. Hypertension. 2007;50:228–33.
29. Carretero OA, Oparil S. Essential hypertension part I: definition and etiology.
Circulation. 2000;101:329–35.
30. MacMahon SW, Blacket RB, Macdonald GJ, Hall W. Obesity, Alcohol
Consumption and Blood Pressure in Australian Men and Women The
National Heart Foundation of Australia Risk Factor Prevalence Study. J
Hypertens. 1984;2:85–91.
31. Barreto SM, Passos VMA, Firmo JOA, Guerra HL, Vidigal PG, Lima-Costa MFF.
Hypertension and clustering of cardiovascular risk factors in a community in
Southeast Brazil: the Bambuí Health and Ageing Study. Arq Bras Cardiol.
2001;77:576–81.
32. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/
ESC Guidelines for the management of arterial hypertension The Task Force
for the management of arterial hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur
Heart J. 2013;2013(34):2159–219.
Alhawassi et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:24 Page 5 of 6
33. Huebschmann AD, Bublitz C, Anderson RJ. Are hypertensive elderly patients
treated differently? Clin Interv Aging. 2006;1:289.
34. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.
Treatment of hypertension in patients 80 years of age or older. N Engl J
Med. 2008;358:1887–98.
35. Dahlöf B, Hansson L, Lindholm L, Schersten B, Ekbom T, Wester P. Morbidity
and mortality in the Swedish trial in old patients with hypertension (STOP-
Hypertension). The Lancet. 1991;338:1281–5.
36. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, et al.
Randomised trial of old and new antihypertensive drugs in elderly patients:
cardiovascular mortality and morbidity the Swedish Trial in Old Patients
with Hypertension-2 study. The Lancet. 1999;354:1751–6.
37. Davis B, Cutler JA, Gordon D. Major outcomes in high risk hypertensive
patients randomized to angiotensin-converting enzyme inhibitor or calcium
channel blocker vs diuretic: The Antihypertensive and Lipid Lowering
treatment to prevent Heart Attack Trial (ALLHAT). Jama. 2002;288:2981–97.
38. Triantafyllou A, Douma S, Petidis K, Doumas M, Panagopoulou E, Pyrpasopoulou
A, et al. Prevalence, awareness, treatment and control of hypertension in an
elderly population in Greece. Rural Remote Health. 2010;10(1225).
39. Prencipe M, Casini A, Santini M, Ferretti C, Scaldaferri N, Culasso F.
Prevalence, awareness, treatment and control of hypertension in the elderly:
results from a population survey. J Hum Hypertens. 2000;14:825–30.
40. Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiener JS, Burke GL, et al.
Time trends in high blood pressure control and the use of antihypertensive
medications in older adults: the Cardiovascular Health Study. Arch Intern
Med. 2002;162:2325–32.
41. Van Kraaij D, Jansen R, Gribnau F, Hoefnagels W. Loop diuretics in patients
aged 75 years or older: general practitioners’ assessment of indications and
possibilities for withdrawal. Eur J Clin Pharmacol. 1998;54:323–7.
42. Van Kraaij DJ, Jansen RW, De Gier JJ, Gribnau FW, Hoefnagels WH.
Prescription patterns of diuretics in Dutch community‐dwelling elderly
patients. Br J Clin Pharmacol. 1998;46:403–7.
43. Onder G, Gambassi G, Landi F, Pedone C, Cesari M, Carbonin P, et al. Trends
in antihypertensive drugs in the elderly: the decline of thiazides. J Hum
Hypertens. 2001;15:291–7.
44. Moser M. Why are physicians not prescribing diuretics more frequently in
the management of hypertension? Jama. 1998;279:1813–6.
45. Rodriguez-Roca GC, Llisterri JL, Prieto-Diaz MA, Alonso-Moreno FJ,
Escobar-Cervantes C, Pallares-Carratala V, et al. Blood pressure control and
management of very elderly patients with hypertension in primary care
settings in Spain. Hypertens Res. 2013;37:166–71.
46. Tu K, Campbell NR, Chen Z, McAlister FA. Thiazide diuretics for
hypertension: prescribing practices and predictors of use in 194,761 elderly
patients with hypertension. Am J Geriatr Pharmacother. 2006;4:161–7.
47. Svetkey LP, George LK, Tyroler HA, Timmons PZ, Burchett BM, Blazer DG.
Effects of gender and ethnic group on blood pressure control in the elderly.
Am J Hypertens. 1996;9:529–35.
48. Barker WH, Mullooly JP, Linton KL. Trends in hypertension prevalence,
treatment, and control in a well-defined older population. Hypertension.
1998;31:552–9.
49. Prince MJ, Ebrahim S, Acosta D, Ferri CP, Guerra M, Huang Y, et al.
Hypertension prevalence, awareness, treatment and control among older
people in Latin America, India and China: a 10/66 cross-sectional
population-based survey. J Hypertens. 2012;30:177–87.
50. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A
comparison of outcomes with angiotensin-converting–enzyme inhibitors
and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.
51. Parving H-H, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon
SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N
Engl J Med. 2012;367:2204–13.
52. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al.
Effect of aliskiren on postdischarge mortality and heart failure readmissions
among patients hospitalized for heart failure: the ASTRONAUT randomized
trial. Jama. 2013;309:1125–35.
53. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al.
Randomised double-blind comparison of placebo and active treatment for
older patients with isolated systolic hypertension. The Systolic Hypertension
in Europe (Syst-Eur) Trial Investigators. The Lancet. 1997;350:757–64.
54. Pahor M, Guralnik JM, Ferrucci L, Corti M-C, Salive ME, Cerhan JR, et al.
Calcium-channel blockade and incidence of cancer in aged populations.
The Lancet. 1996;348:493–7.
55. Pahor M, Carbonin P, Guralnik J, Havlik R, Furberg C. Risk of gastrointestinal
haemorrhage with calcium antagonists in hypertensive persons over
67 years old. The Lancet. 1996;347:1061–5.
56. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C,
et al. Influences of educational interventions and adverse news about
calcium-channel blockers on first-line prescribing of antihypertensive drugs
to elderly people in British Columbia. The Lancet. 1998;352:943–8.
57. Larochelle P, Tobe SW, Lacourcière Y. β-Blockers in Hypertension: Studies
and Meta-analyses Over the Years. Can J Cardiol. 2014;30:S16–22.
58. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in
England: a serial cross-sectional study from. 2011. The Lancet.
1994;2014(383):1912–9.
59. Schäfer H-H, De Villiers JN, Sudano I, Dischinger S, Theus G-R, Zilla P.
Dieterle T. Swiss Med Wkly Epub: Recommendations for the treatment of
hypertension in the elderly and very elderly–a scotoma within international
guidelines; 2012.
60. Psaty BM, Koepsell TD, Yanez ND, Smith NL, Manolio TA, Heckbert SR, et al.
Temporal patterns of antihypertensive medication use among older adults,
1989 through 1992: an effect of the major clinical trials on clinical practice?
Jama. 1995;273:1436–8.
61. Alhawassi TM, Krass I, Pont LG. Hypertension in Older Persons: A Systematic
Review of National and International Treatment Guidelines. J Clin Hypertens.
2015;17:486–492. doi:10.1111/jch.12536.
62. Cranney M, Barton S, Walley T. Addressing barriers to change: an RCT of
practice-based education to improve the management of hypertension in
the elderly. Br J Gen Pract. 1999;49:522–6.
63. Onder G, Gambassi G, Sgadari A, Williamson JD, Cesari M, Landi F, et al.
Impact of hospitalization on blood pressure control in Italy: results from the
Italian Group of Pharmacoepidemiology in the Elderly (GIFA).
Pharmacotherapy: The Journal of human pharmacology and drug therapy.
2003;23:240–7.
64. Eastman P. Antihypertensive prescribing: A survey of general practice
supervisors and registrars. Aust Fam Physician. 2008;37:969.
65. Fotherby M, Harper G, Potter J. General practitioners’ management of
hypertension in elderly patients. BMJ [Br Med J]. 1992;305:750.
66. Wang PS, Avorn J, Brookhart MA, Mogun H, Schneeweiss S, Fischer MA, et
al. Effects of noncardiovascular comorbidities on antihypertensive use in
elderly hypertensives. Hypertension. 2005;46:273–9.
67. Brindel P, Hanon O, Dartigues J-F, Ritchie K, Lacombe J-M, Ducimetière P, et
al. Prevalence, awareness, treatment, and control of hypertension in the
elderly: the Three City study. J Hypertens. 2006;24:51–8.
68. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and
management of hypertension, dyslipidemia, and diabetes among United
States adults aged 65 and older. J Gerontol A Biol Sci Med Sci.
2009;64:256–63.
69. Al Ghatrif M, Kuo Y-F, Al Snih S, Raji MA, Ray LA, Markides KS. Trends in
hypertension prevalence, awareness, treatment and control in older
Mexican Americans, 1993–2005. Ann Epidemiol. 2011;21:15–25.
70. De Backer G, Myny K, De Henauw S, Doyen Z, Van Oyen H, Tafforeau J, et al.
Prevalence, awareness, treatment and control of arterial hypertension in an
elderly population in Belgium. J Hum Hypertens. 1998;12:701–6.
71. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The Effects of
Initial Drug Choice and Comorbidity on Antihypertensive Therapy
Compliance* Results From a Population-Based Study in the Elderly.
Am J Hypertens. 1997;10:697–704.
72. Hsu Y-H, Mao C-L, Wey M. Antihypertensive Medication Adherence Among
Chinese Americans. J Transcult Nurs. 2010;21(4):297–305.
73. Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C. Barriers to
adherence and hypertension control in a racially diverse representative
sample of elderly primary care patients. Pharmacoepidemiology and Drug
Safety. 2009;18:672–81.
74. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to
and determinants of medication adherence in hypertension management:
perspective of the cohort study of medication adherence among older
adults. Med Clin North Am. 2009;93:753–69.
75. Butt T, Branch R, Beesley L, Martin U. Managing hypertension in the very
elderly: effect of adverse drug reactions (ADRs) on achieving targets. J Hum
Hypertens. 2010;24:514–8.
76. Sato I, Akazawa M. Polypharmacy and adverse drug reactions in Japanese
elderly taking antihypertensives: a retrospective database study. Drug,
Healthcare and Patient Safety. 2013;5:143.
Alhawassi et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:24 Page 6 of 6
